Synopsys Inc. SNPS shares have plunged 22.4% in the past year, underperforming the Zacks Computer and Technology sector and the S&P 500 index’s return of 7.8% and 9.5%, respectively. The stock has ...

Synopsys’ (SNPS) CEO Sassine Ghazi, recently sold the company’s shares worth $5.37 million. SNPS is a software company that ...

Synopsys (SNPS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Adolescent BMI amplifies genetic risk for high blood pressure, with sex-specific differences in how BMI modifies SBP ...

In this article, we are going to take a look at where Synopsys, Inc. (NASDAQ:SNPS) stands against the other oversold blue ...

Shares of Synopsys Inc. SNPS advanced 1.16% to $450.88 Friday, on what proved to be an all-around favorable trading session ...

Synopsys and Cadence, beyond EDA software, provide Intellectual Property and collect licensing and royalty fees. Click to ...

Below is Validea's guru fundamental report for SYNOPSYS INC (SNPS). Of the 22 guru strategies we follow, SNPS rates highest using our P/B Growth Investor model based on the published strategy of ...

Synopsys (SNPS) issued the following statement in response to the U.K. Competition and Markets Authority’s, or CMA, recently published decision ...

Nursing home patients’ enrollment in I-SNPs has been tied to better performance on six of eight major indicators.

About half of these individuals (54 percent) are enrolled in MA Dual-Eligible Special Needs Plans (D-SNPs), specialized MA plans that only enroll dually eligible individuals. Due to higher rates ...